M
Michael Hughes
Researcher at Royal Hallamshire Hospital
Publications - 615
Citations - 26328
Michael Hughes is an academic researcher from Royal Hallamshire Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 74, co-authored 531 publications receiving 24066 citations. Previous affiliations of Michael Hughes include Royal College of Physicians & St Thomas' Hospital.
Papers
More filters
Proceedings ArticleDOI
Dual mode fibre bundle confocal endomicroscopy: combining reflectance and fluorescence imaging
TL;DR: In this paper, a combination of polarisation selection and refractive index matching is used to minimise back-reflections from the fibre bundle in a confocal endomicroscope, which acquires simultaneous and co-registered fluorescence and reflectance images.
Journal ArticleDOI
Treatment of Vascular Complications in Systemic Sclerosis: What Is the Best Approach to Diagnosis and Management of Renal Crisis and Digital Ulcers?
TL;DR: In this paper , the diagnosis and management of scleroderma renal crisis (SRC) and digital ulcers (DUs) in systemic sclerosis (SSc) is discussed.
Journal ArticleDOI
Pos0900 systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review
Nancy Maltez,Lauren Ross,Michael Hughes,Jan W. Schoones,Murray Baron,L. Chung,Chiara Mormile Di Campochiaro,Yossra A. Suliman,Dilia Giuggioli,Pia Moinzadeh,Yannick Allanore,CD Denton,O. Distler,Tracy M. Frech,D. E. Furst,Dipti Khanna,T. Krieg,Masataka Kuwana,Marco Matucci-Cerinic,Jennifer Pope,Alessia Alunno +20 more
TL;DR: To summarise data on efficacy and safety of systemic treatments for SSc DU, a systematic literature review to May 2021 was performed and all treatments were generally tolerated with few serious adverse events.
Journal ArticleDOI
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
Teresa H. Evering,Kara W. Chew,Mark J. Giganti,Carlee Moser,Mauricio Pinilla,David A. Wohl,Judith S. Currier,Joseph J. Eron,Arzhang Javan,Rachel A Bender Ignacio,D. Margolis,Qing Zhu,Ji Ma,Lijie Zhong,Li Yan,Keila Hoover,Bharat Mocherla,Manish Chandra Choudhary,Rinki Deo,Justin Ritz,William A. Fischer,Courtney V. Fletcher,Jonathan Z. Li,Michael Hughes,Davey M. Smith,Eric S. Daar +25 more
TL;DR: In an international National Institutes of Health sponsored trial of combination SARS-CoV-2 neutralizing antibodies, investigators determined not only overall efficacy and safety but also whether there was a benefit of administration more than 5 days after symptom onset as discussed by the authors .